AI summary & topic connections
Reports genetic, cardiovascular and neurological conditions and concerns about cumulative exposure, proposes biological susceptibility mechanisms, and requests genotype-stratified research and standards protective of vulnerable groups.
- Proposed biological mechanisms:
genetic/metabolic modifiers of RF/EMF response
- Heart symptoms & implanted devices:
cardiac issues, hypertension of undetermined cause
- Research & federal duties:
genotype-stratified studies
- Children & vulnerable groups:
Q11 (Children)
- Exposure limits & oversight:
evaluate whether current standards protect vulnerable groups
RE: Request for Information on Electromagnetic Fields (EMFs), Radiofrequency (RF) Radiation, and Wireless Radiation Exposure
Docket: HHS-OASH-2026-0397
Perspective (Q2): Individual with compound heterozygous MTHFR (C677T + A1298C), elevated homocysteine, atherosclerosis with plaque, osteoarthritis, chronic tinnitus, cardiac issues, hypertension of undetermined cause, and hypersensitivity to medications, chemicals, and environmental factors.
I submit this comment to share personal experiences and support research on vulnerable populations.
Q3: I experience chronic tinnitus, cardiac issues, hypertension of undetermined cause, elevated homocysteine, atherosclerosis with plaque, and osteoarthritis. I am highly hypersensitive to medications, chemicals, and other exposures. I also have fatigue, sleep disruption, and cognitive difficulties (brain fog, concentration/memory problems). These have not been fully explained by standard evaluations. I am concerned that cumulative or modulated RF/EMF exposures may contribute or exacerbate symptoms given my genetic background and elevated homocysteine.
Q11: I am compound heterozygous for MTHFR C677T and A1298C with elevated homocysteine and atherosclerosis. This genotype substantially reduces enzyme activity (~30–50% of normal), impairing methylation, raising homocysteine risk, lowering glutathione, and increasing oxidative stress vulnerability. Elevated homocysteine is a cardiovascular risk factor and can affect NMDA receptors and calcium signaling.
Proposed non-thermal RF/EMF mechanisms (voltage-gated calcium channel activation, excess intracellular calcium, nitric oxide/peroxynitrite, and reactive oxygen species) may interact with these vulnerabilities. People with this genotype, elevated homocysteine, chemical hypersensitivity, or cardiovascular disease may be a sensitive subgroup not fully protected by thermal-only limits.
Q11 (Children): A 2026 study (Wydaeghe et al., Phys Med Biol 71:175006) found child models had 1.5–1.9× higher whole-body SAR than adults below 6 GHz. Beamforming created local SAR hotspots exceeding limits even when external exposure met reference levels.
Q12: Salford et al. (1994) reported increased blood-brain barrier permeability in rats after 915 MHz exposure. Larger studies (NTP, Ramazzini) also found effects at higher levels. Further research is needed on non-thermal effects in susceptible individuals.
Q13/Q16: Wireless Body Area Networks operate close to the body in RF bands including 2.4 GHz (Zhong et al., Sensors 2022, 22:3539). Real-world multi-source exposures and 5G beamforming differ from single-source assumptions. Priorities should include genotype-stratified studies (MTHFR compound heterozygotes), people with elevated homocysteine or cardiovascular disease, chemical/electromagnetic hypersensitivity, cumulative exposure methods, and transparent disclosure of device/infrastructure metrics.
I urge HHS, FDA, NIH, and CDC to take reports of unexplained tinnitus, cardiac issues, hypertension, elevated homocysteine, atherosclerosis, osteoarthritis, and hypersensitivity seriously; fund independent research on genetic/metabolic modifiers of RF/EMF response; and evaluate whether current standards protect vulnerable groups.
Thank you.
Supporting references:
Wydaeghe et al. 2026
https://doi.org/10.1088/1361-6560/ae97ac
Salford et al. 1994
https://pubmed.ncbi.nlm.nih.gov/8012056
Zhong et al. 2022
https://doi.org/10.3390/s22093539